Genetix Biotherapeutics Inc.
Somerville · Founded 2010
About Genetix Biotherapeutics Inc.
Genetix Biotherapeutics is a privately-held, commercial-stage biotechnology company dedicated to delivering potentially curative genetic therapies for patients living with severe rare diseases.The company focuses on developing and commercializing one-time administered gene therapies that directly treat the underlying genetic cause of the disease. They currently have FDA-approved treatments for:Sickle Cell Disease (Product: LYFGENIA)$\beta$-thalassemia (Product: ZYNTEGLO)Cerebral Adrenoleukodystrophy (CALD) (Product: SKYSONA)With a foundation of over 30 years of genetic therapy innovation, Genetix Biotherapeutics is committed to scaling patient access, commercial execution, and improving the overall treatment experience for patients and healthcare providers.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $3.4B
- Funding stage: M&A
- Last round: Private Equity (Feb 2025)
- Ticker: nasdaq:BLUE
- Website: genetixbiotx.com
- Phone: 339-499-9300
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Oncology, Pharmaceutical
Canonical: https://fsome.com/organization/genetix-biotherapeutics-inc-86221 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.